In The Claims

Please amend the claims as follows:

What is claimed is:

1. (currently amended) A ~~Combined~~ combined cosmetic or therapeutic preparation having a carrier system comprising membrane-forming lipids and at least two active ingredients which are selected from at least two of the groups

(a) anti-coagulants,

(b) vasoprotective agents and

(c) microcirculation-promoting substances.

2. (currently amended) A combined preparation according to claim 1 ~~characterised in that~~ wherein the active ingredients are selected from the groups anti-coagulants (a) and vasoprotective agents (b).

3. (currently amended) A combined preparation according to claim 1 ~~characterised in that~~ wherein the active ingredients are selected from the groups anti-coagulants (a) and microcirculation-promoting substances (c).

4. (currently amended) A combined preparation according to claim 1 ~~characterised in that~~ wherein the active ingredients are selected from the groups vasoprotective agents (b) and microcirculation-promoting substances (c).

5. (currently amended) A combined preparation according to claim 1 ~~characterised in that~~ wherein the active ingredients are selected from the groups anti-coagulants (a), vasoprotective agents (b) and microcirculation-promoting substances (c).

6. (currently amended) A combined preparation according to claim 1 ~~one of claims 1 to 5 characterised in that~~ wherein the carrier system is vesicular.

7. (currently amended) A combined preparation according to claim 1 ~~one of claims 1 to 6 characterised in that~~ wherein the membrane-forming lipids include the groups of phospholipids, ceramides and diacylglycosides.

8. (currently amended) A combined preparation according to claim 1 ~~one of claims 1 to 7 characterised in that~~ wherein the membrane-forming lipids contain at least 70 % by weight of phosphatidylcholine, preferably about 80 – 90 % by weight of phosphatidylcholine.

9. (currently amended) A combined preparation according to claim 1 ~~one of claims 1 to 3 and 5 to 8 characterised in that~~ wherein the anti-coagulants are selected from heparins, fucoidans, hirudins, pentapeptides, coumarin derivatives and mixtures thereof.

10. (currently amended) A combined preparation according to claim 1 ~~one of claims 1 to 3 and 5 to 9 characterised in that~~ wherein as the anti-coagulant it contains fucoidan, preferably low-molecular fucoidan, particularly preferably in an amount of 0.1 – 10 % by weight. (currently amended)

11. (currently amended) A combined preparation according to claim 1 ~~one of claims 1, 2 and 4 to 10 characterised in that~~ wherein the vasoprotective agents are selected from aescin, rutin, diosmin, ruscogenin and mixtures thereof.

12. (currently amended) A combined preparation according to claim 1 ~~one of claims 1, 2 and 4 to 11 characterised in that~~ wherein it contains aescin as the vasoprotective agent, preferably in an amount of 0.1 – 7 % by weight.

13. (currently amended) A combined preparation according to claim 1 ~~one of claims 1 and 3 to 12 characterised in that~~ wherein the microcirculation-promoting substances are selected from

caffeine, naftidrofuryl, pentoxyfyllin, buflomedil and ginkgo active ingredients and mixtures thereof.

14. (currently amended) A combined preparation according to claim 1 ~~one of claims 1 and 3 to 13 characterised in that~~ wherein it contains caffeine as the microcirculation-promoting substance, preferably in an amount of 0.1 - 2 % by weight.

15. (currently amended) A combined preparation according to claim 1 ~~one of claims 1 and 5 to 14 characterised in that~~ wherein it contains aescin, preferably in an amount of 4.0 to 6.0 % by weight, particularly preferably 5.0 % by weight, low-molecular fucoidan, preferably in an amount of 1.0 to 3.0 % by weight, particularly preferably 2.0 % by weight, and caffeine, preferably in an amount of 0.5 to 1.5 % by weight, particularly preferably 1.0 % by weight.

16. (currently amended) A combined preparation according to claim 1 ~~one of claims 1 to 15 characterised in that~~ wherein the carrier system additionally contains linoleic acid in stabilised form, preferably in an amount of 2.5 to 4.5 % by weight.

17. (currently amended) A combined preparation according to claim 1 ~~one of claims 1 to 16 characterised in that~~ wherein it further contains at least one thermoreceptor-agonist which is selected from the group which includes natural or synthetic capsaicin, preferably in an amount of 0.1 to 1 % by weight, particularly preferably in an amount of 0.2 to 0.6 % by weight, and nicotinic acid, nicotinic acid amide, nicotinic acid ester or mixtures thereof, preferably in an amount of 0.5 to 5 % by weight, particularly preferably in an amount of 0.5 to 3 % by weight.

18. (currently amended) A combined preparation according to claim 1 ~~one of claims 1 to 17 characterised in that~~ wherein it further contains 10 – 25 % by weight of ethanol.

19. (currently amended) A method for the production of a preparation ~~cosmetic or drug~~ for prophylaxis and/or treatment of hematomas comprising combining ~~Use of~~ membrane-forming lipids and at least two active substances which are selected from at least two of the groups (a)

anti-coagulants, (b) vasoprotective agents and (c) microcirculation-promoting substances. [[,]] ~~for the production of a cosmetic or drug for prophylaxis and/or treatment of hematomas, preferably hematomas of the lower eyelid, and/or vein complaints .~~

20. (new) The method of claim 19 wherein the preparation is for phophylaxis or treatment of hematomas of the lower eyelid, and/or veins.